Introduction
Adoptive immunotherapy (AIT) using antigen-sensitized T cells activated and/or expanded in vitro has been extensively investigated as a potential therapy for cancer in humans [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . We have shown that in vitro treatment with bryostatin 1 and ionomycin (B/I) selectively activates antigensensitized tumor draining lymph node (tDLN) lymphocytes [7] [8] [9] [10] 12] . Bryostatin 1, a macrocyclic lactone derived from Bugula neritina, activates protein kinase C, and ionomycin increases intracellular calcium, mimicking signaling through the CD3/T cell receptor (TcR) complex, and leading to activation and proliferation of T cells [13] [14] [15] [16] .
In the 4T1 mammary carcinoma model which is very weakly immunogenic and aggressively metastatic, we have previously shown that B/I selectively activates CD62L
-or sensitized T cells [12] . Although our previous studies in this model were based on the use of the T cell growth factor interleukin-2 (IL-2) to stimulate the proliferation of antitumor T cells in culture, other cytokines that stimulate T cell growth, via a gamma chain shared with the IL-2 receptor complex, may have a number of important advantages. In particular, IL-7 and IL-15 support the proliferation and survival of T cells more effectively than IL-2 does, and we have reported recently, in the B16 melanoma model, that culturing B/I-activated DLN cells in IL-7 ? IL-15 resulted in much greater proliferation and improved survival of T cells than the same type cells grown in IL-2 [17] . T cells grown in IL-7/15 were consistently at least as effective as T cells grown in IL-2 at inducing regression of melanoma lung metastases. IL-7/15 are also less likely to stimulate growth of Treg cells, which respond to IL-2 and may suppress antitumor immune responses [18] [19] [20] [21] [22] [23] [24] . Moreover, these alternate gamma-chain cytokines have been found to support preferential differentiation of CD8? T cells toward a central memory (Tcm) phenotype, which, as suggested by some researchers, may be more effective at inducing tumor regression than the effector cells that are more likely to develop when lymphocytes are grown in IL-2 [25] [26] [27] [28] . IL-15 also favors greater survival of high versus low avidity cytotoxic T lymphocytes, and higher expression of the CD8 coreceptor [29] . Although we observed a shift in the phenotypes for melanoma-specific T cells grown in IL-7/15 compared with cells grown in IL-2, they were only slightly more effective at inducing regression of melanoma lung metastases at equivalent cell doses. Thus, the major advantage of IL-7/15 over IL-2 in the melanoma model related to the greater yield of viable T cells, and not to any major increase in their in vivo activity.
In this article, however, we show that 4T1 mammary carcinoma-specific T cells activated with B/I not only grow far more rapidly and for a longer time when cultured in IL-7/15 than in IL-2, but also are far more effective at mediating regression of established subcutaneous 4T1 tumors than the same cells grown in IL-2.
Methods

Mice
Virus-free BALB/c mice (National Cancer Institute, Bethesda, MD) and between 8 and 12 weeks of age, caged in groups of six or fewer, were provided with food and water ad libitum. All guidelines of the Virginia Commonwealth University Institutional Animal Care and Use Committee, which conform to the American Association for Accreditation of Laboratory Animal Care and the U.S. Department of Agriculture recommendations for the care and humane experimental use of animals, were followed.
Tumor cell lines 4T1 mammary tumor cell line was kindly provided by Dr. Jane Tsai of the Michigan Cancer Foundation, Detroit, Michigan. Cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) with 10% heat-inactivated fetal calf serum (Hyclone, Logan, UT), 1 mM sodium pyruvate, 100 U/ml penicillin, and 100 lg/ml streptomycin (Sigma, St. Louis MO) (modified DMEM). Tumor cells were harvested for inoculation of mice with 0.05% trypsin-EDTA (Fisher, Pittsburgh, PA).
Draining lymph node sensitization Donor mice were vaccinated in the left hind footpad with 1 9 10 6 viable 4T1 cells. Ten days after footpad vaccination, when these mice had a growing tumor in the foot, popliteal tDLNs were harvested under sterile conditions.
Lymphocyte activation and in vitro expansion
Draining lymph nodes were harvested and dispersed into a single cell suspension in complete RPMI media at 1 9 10 6 cells/ml. The cells were activated by incubation with 5 nM bryostatin 1 (provided by the National Cancer Institute, Bethesda, MD) and 10 nM ionomycin (Calbiochem, San Diego, CA) (B/I), and 80U/ml of rIL-2 (Chiron, Emeryville, CA) at 37°C for 18 h. Cells were washed three times with warm, complete RPMI and resuspended at 1-2 9 10 6 cells/ml with 40 U/ml of rIL-2 or in IL-7 ? IL-15 (10 ng/ml each). The cells were allowed to proliferate in culture for an additional 6-14 days and were split every 2-3 days to maintain 1-2 9 10 6 cells/ml concentration. Fresh cytokines were added at each split to achieve the same final concentration as at culture initiation. Samples were assessed for the number of viable cells, by trypan blue exclusion, at various days of culture (usually at the time of splits), as shown.
Adoptive immunotherapy
Host mice were inoculated in the left flank with 2.5 9 10 4 -5 9 10 4 4T1 cells. One day prior to AIT, mice were pretreated with cyclophosphamide (CYP, Mead Johnson, Princeton, NJ), 100 mg/kg intraperitoneally (IP). After various time points in culture, (usually 6-10 days), the B/Iactivated and expanded DLN lymphocytes were washed twice in phosphate buffered saline, filtered through a 70-lm nylon mesh strainer (Invitrogen, Carlsbad, CA), and injected intravenously (IV) in 0.5 ml into host mice. No systemic cytokines or vaccinations were administered to these tumor-bearing mice.
Flow cytometry
Cells harvested from cultures at various time points were stained with a panel of antibodies and analyzed by dual color flow cytometry for surface marker expression on an ELITE Beckman Coulter flow cytometer. Fluorescently labeled Abs directed against the following markers were obtained from Pharmingen (San Diego, CA): CD4 (GK1.5), CD8 (53-6.7), CD44 (IM7), CD62L (MEL-14), and CD69 (H1.2F3). Intracellular staining for Foxp3 was also performed on permeabilized cells, using PE antimouse/rat Foxp3 staining set (eBioscience, San Diego, CA). Appropriate isotype controls were used in all the cases.
Proliferation assays
Lymphocytes activated with B/I were cultured in 96-well plates (at either 12,000 or 25,000 viable cells per well in 0.2 ml) in IL-2 (40U/ml) or IL-7/15 (10 ng/ml each). After 3-9 days of culture, the cells were labeled with 1 lCi per well of [ 3 H]thymidine (PerkinElmer Life and Analytical Sciences, Boston, MA) and were harvested 24 h later with a semiautomated harvester (PHD: Cambridge Technology, Inc., Cambridge, MA). Thymidine uptake was determined by liquid scintillation counting and expressed as the mean cpm ± SD of triplicate wells.
Tumor measurements
In all the AIT experiments, tumor growth was monitored with biweekly measurements of perpendicular diameters. Results are reported as the mean tumor area ± standard error (SE). When the tumor area was greater than 100 mm 2 or if a mouse appeared ill, then the animal was euthanized by CO 2 inhalation. Complete tumor regression was defined as the absence of a measurable tumor on three consecutive measurements.
Cytokine release assays
Interferon-c (IFN-c) release in supernatants from tumorsensitized and B/I-activated and expanded lymphocytes, in response to stimulation with irradiated 4T1 for 24 h, was assayed using BD OptEIA mouse IFN-c ELISA sets from BD Biosciences (San Jose, CA).
Statistical analysis
Differences in tumor growth and in vitro assay results (proliferation and IFN-c release) were assessed by repeated measures analysis of variance (ANOVA) and Tukey-Kramer honestly significant difference test (Tukey's HSD) using PROC GLIMMIX, version 9.2 (SAS Institute Inc., Cary, N.C.). In vivo experiments included at least six mice per group and were repeated at least twice. A value of P \ 0.05 was used throughout to determine significant differences. Descriptive statistics shown are means ± standard errors (SEMs). B/I activation, while the same cells grown in IL-2 started to decline in number after day 5 or day 6 and usually had to be discarded before day 10 because of poor viability. In several experiments (Fig. 1b) , IL-7/15-cultured cells expanded 30-70-fold before 2 weeks, without any restimulation with antigen or B/I. The results shown in Fig. 1 are representative of more than a dozen separate experiments. For nine separate experiments in which both IL-2 and IL-7/ 15 cultured cells were counted on day 7, the median expansions were 9-and 32-fold, respectively. In order to determine whether the increased yield of cells in IL-7/15 resulted from an increase in proliferation, B/I-activated DLN cells resuspended in either IL-2 or IL-7/ 15 were pulsed with tritiated thymidine at various days of culture and assessed for thymidine incorporation 24 hours later. As shown in Fig. 2 , proliferation was dramatically higher for cells grown in IL-7/15 at both day 6 and day 9. In addition, part of the increased yield of viable cells in alternate cytokines was accounted for by the higher proportion of dead cells (as assessed by trypan blue uptake) in IL-2. For example, at days 3, 6, 9, and 12 in one experiment, the proportions of dead cells in IL-2 were 7.3, 13.5, 30, and 36% versus 1.5, 6.4, 23, and 13% in IL-7/15, respectively (representative of 3 separate experiments).
Results
Expansion
Phenotypes of cells grown in IL-7/15 versus IL-2
Analysis of the phenotypes grown in different cytokines showed some key differences in the resulting distribution of phenotypes. As shown in Table 1 , B/I-activated lymph node cells grown in IL-7/15 had higher proportions of CD8?, CD62L?, and CD69? cells than cells grown in IL-2. Moreover, with double-staining analysis, IL-7/15 cultured cells had a higher proportion of CD44?CD62L? double-positive memory cells (Fig. 3) . These results are representative of three separate experiments, which are summarized in Table 2 . With triple-staining, it was possible to determine that the proportion of CD8? cells with memory cell phenotypes, as shown in Fig. 4 , became higher when cells were grown in IL-7/15. Also, note that on day 9, the CD8? cells grown in IL-2 were nearly evenly divided between low and high CD8 expressing cells, while nearly all the CD8? cells grown in IL-7/15 were CD8
high . In addition, as the cultures were continued over time, Treg cells, detected as triple-positive CD4?CD25?Foxp3? cells (Fig. 5) , at first declined, but at later time points were more frequent among CD4? cells grown in IL-2 (14.2, 7.3, and 7.6% on days 2, 6, and 9, respectively) compared to cells grown in IL-7/15 (15, 2.7, and 2.6% on the same days as above). Moreover, as shown in Even with doses as low as 9 million IL-7/15-cultured cells per mouse, 2/5 mice were cured, with a tumor growth curve for the overall group that was similar to that obtained with 75 million IL-2-grown cells (data not shown).
Memory function in cured mice and in naïve mice not previously exposed to tumor When mice that had been cured and did not develop metastases over a 2-month period after AIT with either IL-2 or IL7/15-cultured T cells were rechallenged with 4T1 tumor cells, most of the cured mice were completely resistant to tumor growth, compared to none of the controls (Fig. 9a, b) . Prior to the experiment shown in Fig. 9a , the mice challenged were initially cured by AIT with 75 9 10 6 cells grown either in IL-2 or IL-7/15. Three out of three is for the group that had received IL-2 cultured cells (only three out of six mice remained tumor-free at 2 months), and 5/5 is for group that had received cells cultured in IL-7/ 15 (5/7 remained tumor-free at 2 months). Both the groups were significantly different from CON [F(1,33) = 144.7 and 179.0 for IL-2 and IL-7/15 AIT vs CON, respectively, P \ 0.0001]. In the experiment depicted in Fig. 9b , mice had been cured with AIT using cells cultured in IL-7/15, at either 25 or 50 9 10 6 cells per mouse. All but one mouse initially treated with AIT using IL-7/15 cultured cells were tumor-free at 2 months. Both the groups were significantly different from CON [F(1,82) = 37.9 and 158.00 for IL-7/ 15 AIT at 25 and 50 million cells vs CON, respectively, P \ 0.0001]. It is worth noting that AIT, especially with IL-7/15 cultured cells, induced not only regression of the primary tumors but also long-term cures in most of the In order to determine whether this immunologic memory response was actually a function of the adoptively transferred cells or reflected sensitization of the host T cells by the inoculated tumor, we adoptively transferred B/Iactivated 4T1 DLN cells into naïve mice, and the naïve mice and control mice were inoculated with 4T1 tumor cells 3 weeks later. None of these mice received CYP, cytokines, nor were they ever exposed to tumor antigen prior to the challenge. As shown in Fig. 9c , mice that received T cells grown in either IL-2 or IL-7/15 were completely resistant to tumor growth. Both the groups were significantly different from CON [F(1,65) = 109.83 for both IL-2 and IL-7/15 vs CON, P \ 0.001].
Discussion
As we have shown previously in the B16 melanoma system, with either of the wild type or TcR transgenic T cells, we now show in a mammary carcinoma that culturing B/Iactivated lymphocytes from tumor-sensitized mice in IL-7/ 15 results in a much higher yield of viable cells than that of the same cells cultured in IL-2. This results from greater proliferation and higher cell viability. Moreover, cells grown in IL-7/15 continue to expand in numbers during a second week in culture, without restimulation via the antigen receptor pathway, while similar cells grown in IL-2 [25, 26] . However, they did not comment on the relative growth of cells in vitro in the two different cytokines. The finding that IL-7 combined with IL-15 was markedly more effective than IL-2 is consistent with the suggestion made previously that, even though both IL-7 and IL-15 have roles in the maintenance and self-renewal of memory precursors, effector CD8? T cells actually need both IL-7 and IL-15 for optimal proliferation and to become long-lived memory cells [32] . The data shown here contrast with those of Carrio et al., who showed that IL-2 induced greater proliferation of CTL than IL-7 or IL-15 alone [33] . The contradictory results may be related to different methods of T cell activation. Carrio et al. activated naïve T cells in vitro with splenocytes pulsed with specific peptide plus IL-2, while our protocol employs pharmacological activation with B/I of T cells previously sensitized by tumor antigen in vivo. It is possible that T cell activation with B/I produces stronger and more prolonged TcR pathway signaling, which would increase the capacity of sensitized T cells to respond to homeostatic cytokines, such as IL-7 and IL-15 [34, 35] . However, in agreement with Carrio et al. and in contrast to what we found in the B16 melanoma model, we did observe a shift away from IFN-c production for cells grown in IL-7/15 versus those grown in IL-2; this is thought to be characteristic of differentiation toward Tcm cells and away from terminally differentiated effector cells [28, 32] . The greater antitumor activity of the IL-7/15 cells in vivo, despite lower effector function, agrees with findings of other authors who have suggested that T cells with greater effector functions, such as cytotoxicity and IFN-c release, may actually be less effective at inducing tumor regression than memory T cells with lower effector function activity [25, 26, 28] . The greater antitumor activity for cells grown in IL-7/15 may also be related to the higher proportion of CD8? cells than what was found for cells grown in IL-2, as we have shown previously that these cells are predominantly responsible for tumor regression in this model [30] . The higher proportion of CD8 high cells after growth in IL-7/15 ( Fig. 4c ) may also help to explain the greater antitumor activity, since CD8 high T cells have higher avidity for target cells than CD8 low T cells and are favored by exposure to IL-15 [29] . The selective survival and proliferation of T cells with higher avidity TcR in the presence of IL-15 may also contribute to greater antitumor activity in vivo.
Days in Culture and
Melchionda et al. showed that IL-7 and IL-15 were comparable to or better than IL-2 at expanding antigensensitized CD8? T cells when given as an adjuvant in vivo along with immunization [27] . However, they found no additive or synergistic effect when IL-7 and IL-15 were combined. In our in vitro B/I activation model, we have shown that the combination of IL-7 and IL-15 has an additive effect on expansion, increasing T cell numbers 7-10-fold over IL-2 and leading to growth that was prolonged at least 2-fold longer in culture. We found that this difference in expansion resulted partly from increased cell viability in IL-7/15, which is consistent with the previously reported protective roles of IL-7 and IL-15 against apoptosis versus the propensity for IL-2 to cause activationinduced cell death [17, 23, [36] [37] [38] [39] [40] .
Although it has been shown that T cells grown in IL-15 persisted longer after adoptive transfer and provided better protection against tumor challenge than cells grown in IL-2, IL-15-expanded T cells were actually less effective at inducing regression of established tumors in a model using OVA-transfected EL-4 [33, 41] . However, Klebanoff et al. found that IL-15-cultured pmel-1 cells were more effective at inducing regression of established s.c. B16 melanomas than T cells cultured in IL-2. This was related to a shift toward a Tcm phenotype, greater proliferation of IL-15 cultured cells in vivo, and increased trafficking to lymphoid tissues [25, 26] . In our previously reported results with a melanoma model, we did observe a moderate shift toward a greater number of CD62L? cells when B/I-activated T cells were cultured in IL-7/15 versus IL-2, but the IL-7/15 cells secreted higher levels of IFN-c in response to tumor antigen and were somewhat more effective at inducing tumor regression than IL-2-cultured cells; but this difference was not as dramatic as the earlier results of Klebanoff et al., or those reported here. This could relate to a number of differences, including the use of antigen-sensitized versus naïve pmel-1 T cells, the use of B/I to reactivate the cells in vitro, treating pulmonary metastases rather than s.c. tumors, or the combined use of IL-7 and IL-15 instead of IL-15 alone. It is possible that the ability of T cells to traffic to lymphoid organs, which has been shown to be favored by the use of IL-15 and the Tcm phenotype, may not be as important for treatment of melanoma pulmonary metastases as it would be for s.c. solid tumors, or for response to a vaccine. Trafficking of cells grown in different cytokines will be explored in our future studies. In the results shown here, however, we found that T cells grown in IL-7/15 developed a higher proportion of cells with a memory phenotype and secreted less IFN-c than cells grown in IL-2 and were dramatically more effective against established s.c. tumors in vivo. This result agrees with the previously reported data suggesting that Tcm with less effector function may be more effective for AIT [25, 26] .
Preliminary studies have been reported with human PBL from melanoma patients vaccinated with a peptide tumor antigen to examine the relative merits of using alternate cytokines to expand T cells for AIT [42] . These studies did not show consistently any major differences in the yield or phenotypes of cells grown in IL-7, IL-15, or combinations compared to IL-2. This finding does not necessarily mean that results similar to what we are reporting here would not be achieved with human T cells, since this may depend on the source of cells, the prior sensitization, and the method of in vitro activation. In addition, the concentration of IL-2 used in the reported human studies was 300 IU/ml, versus 40-80 IU/ml (which we have found to be the optimal concentration for expansion of B/I-activated cells) in our experiments. This concentration also maintains antigen specificity more reliably than higher doses. We also used lower concentrations of IL-7 and IL-15 than those that were used in the human studies. In this mammary carcinoma model, using wild-type tumor-sensitized T cells, we found that IL-7/15-cultured cells were markedly more effective in vivo than cells grown in IL-2 on a per cell basis. Even if the IL-7/15-cultured cells did not function better in vivo, the increased yield of viable cells would still offer a major advantage. This may be of critical importance for clinical use, especially when the number of starting antigen-sensitized T cells is limited. This would likely be the case with vaccine-draining lymph nodes, an approach we plan to apply clinically. The comparatively simple regimen described here, with a modest dose of CYP followed by infusion of T cells cultured for short periods of time, may be particularly applicable to clinical use. Future experiments will examine more detailed comparisons of the in vivo functions, phenotypes, and fates after adoptive transfer of cells grown in IL-7/15 versus those grown in IL-2.
